glp-1 news today september 2025 RA prescription trends: January 2018 – glp-1 news september 30 2025

Limitations The major limitations of the studies that are included in this systematic review are the enrollment of healthy subjects and insufficient data in conditions that might affect pharmacokinetics (e.g., kidney dysfunction)

A major pathological feature of b...

Read more about the new GLP-1 pill that outperformed oral semaglutide in a recent Phase III trial.

GLP-1-related hair loss is called telogen effluvium, which causes sudden, diffuse shedding usually temporary

Currently, there are ten classes of orally available pharmacological agents to treat T2DM: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, 9) sodium-glucose transport protein 2 (SGLT2) inhibitors and 10) oral glucagon like peptide 1 (GLP-1) receptor agonists

Heart failure patients could be the next group to benefit from GLP-1 agonists, which are currently approved for the treatment of diabetes and obesity.